A study to assess whether curcumin can maintain remission in Rheumatoid arthritis while tapering disease modifying anti- rheumatic drugs
- Conditions
- Health Condition 1: null- Rheumatoid arthritisHealth Condition 2: M057- Rheumatoid arthritis with rheumatoid factor without organ or systems involvementHealth Condition 3: M060- Rheumatoid arthritis without rheumatoid factor
- Registration Number
- CTRI/2018/04/013279
- Lead Sponsor
- Dr Padmanabha Shenoy D
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Diagnosed cases of rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria
On conventional DMARDs for at least last six months.
On sustained remission based on DAS 28 (DAS 28 < 2.6) and SDAI � 3.3 and TJC (44) < 0 and SJC (44) < 0 for more than 6 months without requirement of corticosteroids or NSAIDs.
Documented remission status at a minimum of two consecutive visits during last 6 months .
Having other associated rheumatological diseases
Functional class IV
Abnormal liver function (defined as AST/ALT > 3 X upper normal limit ) and active hepatits/cirrhosis
Abnormal renal function / chronic renal failure ( S. creatinine � 2mg/dl)
Those who are currently on curcumin supplements
Known allergic reaction to curcumin
Major comorbidities like severe hypertension , uncontrolled diabetes mellitus , severe respiratory or cardiovascular disease , malignancy
Current or past use of biologics
Current use of Warfarin
Subjects with acute episodes of cholecystitis within last few months
Pregnant and lactating women
Psychiatric or mental disorders
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method